Sun Pharmaceutical Industries announced that US FDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCl liposome injection USP, 2mg/mL, packaged in 20 mg/10mL and 50 mg/25mL single-use vials.
This generic Doxorubicin HCl Liposome injection USP, 2 mg/mL is therapeutically equivalent to Doxil Liposome Injection, 2 mg/mL of Janssen Research and Development, LLC.
Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.
- Advertisement -
